Drugs / NNC0471-0119
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05262595 | Mar → Aug 2022 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04655690 | Nov 2020 → Nov 2021 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0471-0119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05262595 ↗ |
| Modality | Protein / enzyme biologic | “the safety of the new medicine, insulin NNC0471-0119” NCT04655690 ↗ |
| Route | Subcutaneous | “NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.” NCT04655690 ↗ |